Glaucoma: Symptoms, Causes, Treatment and Integrative Support

Glaucoma is a group of eye diseases that damage the optic nerve, the cable that carries what the eye sees to the brain^1,2. In most people it is painless and causes no symptoms until side vision is already lost. That is why about half of the people who have it do not know^1,4. An estimated 4.2 million adults in the United States have glaucoma³. Worldwide it is the leading cause of blindness that cannot be reversed^3,5. Treatment cannot bring back vision that is already gone, but lowering the pressure inside the eye slows or stops further damage in most people^1,2,11. With treatment and regular follow-up, most people with glaucoma do not go blind⁶⁷.

This page explains the types of glaucoma, the symptoms, who is at risk, how it is diagnosed, what treatment exists today and the evidence behind it, which new treatments are in clinical trials, and where integrative care can and cannot fit alongside the care of your eye doctor.

Glaucoma at a glance

On this page

• What is glaucoma?
• Symptoms
• Causes and risk factors
• Diagnosis
• Treatment today
• New treatments in clinical trials
• Living with glaucoma
• Where integrative care fits
• Outlook
• Frequently asked questions
• Sources

What is glaucoma?

The eye makes a clear fluid that drains out through a channel where the iris meets the cornea. Doctors call this channel the drainage angle. When fluid drains too slowly, pressure inside the eye rises and, over time, damages the optic nerve². Pressure is the main risk factor and the only one doctors can treat directly. But it is not the whole story: some people develop glaucoma with pressure in the normal range, and some with high pressure never do^6,8,14.

There are several types^2,17,66:

• Primary open-angle glaucoma is by far the most common type in the United States. The drainage angle looks open, but fluid drains too slowly. It develops over years without pain or early symptoms^1,2.
• Angle-closure glaucoma happens when the iris bulges forward and blocks the angle. It can be sudden (an acute attack, which is an emergency) or slow and chronic^2,7. It is more common in people of East Asian or Inuit descent, in women, in older people, and in people who are farsighted⁷.
• Normal-tension glaucoma is optic nerve damage with eye pressure in the normal range. Blood flow to the nerve and night-time dips in blood pressure may play a part^6,61. Lowering pressure still helps¹⁰. Read our guide to normal-tension glaucoma treatment.
• Secondary glaucoma has another cause: pigment shed from the iris, flaky material on the lens (called exfoliation), inflammation inside the eye, long-term steroid use, injury, or new blood vessels growing over the drainage angle, usually because of diabetes^2,66.
• Childhood (congenital) glaucoma is rare, affecting about 1 in 10,000 babies⁶⁴.

Doctors also use the terms ocular hypertension (pressure above normal with no nerve damage) and glaucoma suspect (borderline findings). Neither is glaucoma. In the largest study of untreated ocular hypertension, fewer than 1 in 10 people developed glaucoma within five years⁸. Our guide to what "glaucoma suspect" means explains what happens next.

Symptoms of glaucoma

Open-angle glaucoma usually has no symptoms at first¹. The nerve fibres that carry side vision are lost first. The earliest change is patchy blind spots in the side vision that the brain fills in, so most people notice nothing until the loss is advanced^1,2. Symptoms that do appear include^1,2,17:

• patches of missing side vision, often starting on the nose side¹
• later, trouble with central vision¹⁷
• in advanced disease, tunnel vision²

Normal-tension glaucoma has the same silent pattern². Pigmentary glaucoma can cause blurred vision or halos after exercise such as jogging².

Acute angle-closure: the symptoms that cannot wait

A sudden rise in pressure causes severe eye pain, a red eye, blurred vision, rainbow-coloured halos around lights, headache, and often nausea and vomiting^1,2,7. This is an eye emergency: without prompt treatment it can cause permanent loss of vision^2,7. Go to an emergency department or call an eye doctor the same day. Our guide to closed-angle glaucoma symptoms covers what happens in the first hours.

What glaucoma vision looks like

Early glaucoma does not look like a dark tunnel. Most people see a complete picture because the brain fills in the gaps. What they notice is practical: a car in the next lane they did not see, a step they missed. By the time vision feels narrow, the loss is usually advanced¹. That is the reason for regular eye exams rather than waiting for symptoms. For the warning signs of each type, read glaucoma warning signs by type.

What causes glaucoma, and who is at risk?

Glaucoma damage happens when the optic nerve cannot tolerate the pressure it is under. For most people that means pressure that is too high. For some, it means a nerve that is unusually vulnerable at normal pressure⁶. Risk rises with^4,6,9:

• Age. Everyone over 60 is at higher risk, and so are Black and Hispanic Americans over 40^1,4.
• Family history. Having a parent or sibling with glaucoma raises your risk substantially^2,4,6. Most adult open-angle glaucoma is caused by many genes acting together rather than one, so routine genetic testing is not recommended⁶³. Our guide answers is glaucoma genetic?.
• Ancestry. Black Americans are roughly two to three times as likely to have glaucoma as white Americans^3,5, and blindness from glaucoma is six to eight times more common⁶⁴. People of East Asian descent are at higher risk of angle-closure⁷.
• Eye pressure. The higher it is, the higher the risk^8,9.
• Thin corneas. A thin central cornea was one of the strongest predictors of who went on to develop glaucoma in the Ocular Hypertension Treatment Study⁹.
• Diabetes, which the CDC says about doubles the risk⁴, and nearsightedness⁶.
• Low blood pressure and poor blood flow to the eye. Both are listed as risk factors in the American Academy of Ophthalmology's 2025 guideline⁶, and night-time dips in blood pressure predicted worsening in people with normal-tension glaucoma⁶¹.
• Long-term steroid use, eye injury, and inflammation inside the eye^2,66.

Sleep apnea appears to be more common in people with glaucoma, though the studies are small and whether it causes glaucoma is unclear⁶². Smoking was not linked to open-angle glaucoma in a 2026 analysis of 26 studies⁶⁰.

For a plain account of which risks matter most, read glaucoma risk factors beyond eye pressure and why glaucoma progresses at normal pressure.

How glaucoma is diagnosed

The only way to diagnose glaucoma is a complete eye exam; a pressure check alone is not enough². A full glaucoma exam includes^2,18:

• Tonometry, which measures eye pressure in millimetres of mercury (mmHg). Normal is usually 10 to 20 mmHg, but the number is a risk factor, not a diagnosis¹⁴. Our guide explains what your eye pressure number means.
• Gonioscopy, a lens that lets the doctor see whether the drainage angle is open or closed.
• Pachymetry, which measures corneal thickness, because a thin cornea raises risk and changes how the pressure reading is read⁹.
• A dilated examination of the optic nerve, looking for the hollowed "cupping" that glaucoma causes.
• Optical coherence tomography (OCT), a scan that measures the thickness of the nerve fibre layer and of the retinal ganglion cells, the nerve cells whose fibres form the optic nerve⁶. Our guide to glaucomatous cupping and OCT explains the scan.
• A visual field test, which maps blind spots in your side vision^1,2.

Eye doctors grade glaucoma by how much damage the nerve and visual field show, and set a lower target pressure for more advanced disease⁶. Because the aim is to catch change over time, the first exam sets a baseline, and the 2025 guideline uses repeated OCT scans and visual field tests together to detect change⁶.

How often to be checked

For adults with no symptoms and no risk factors, the American Academy of Ophthalmology recommends a complete eye exam every 5 to 10 years under 40, every 2 to 4 years from 40 to 54, every 1 to 3 years from 55 to 64, and every 1 to 2 years from 65¹⁵. People with risk factors, including a family history, diabetes, or African or Hispanic ancestry, need exams more often¹⁵. The U.S. Preventive Services Task Force has not found enough evidence to recommend for or against screening in primary care. That is a statement about screening programmes, not about the value of an eye exam for people at risk¹⁶.

Netra Eye Institute does not diagnose or monitor glaucoma. Diagnosis, pressure targets, scans and visual fields belong with your ophthalmologist or optometrist, and we ask every patient to keep that care in place.

Glaucoma treatment today

Every proven treatment for glaucoma works the same way: it lowers eye pressure. Four large randomized trials settled the question. In newly diagnosed patients, lowering pressure cut the share who worsened over six years from 62 percent to 45 percent¹¹. In people with high pressure but no damage, it halved the chance of developing glaucoma over five years⁸. In advanced glaucoma, visual fields stayed almost stable when pressure was under 18 mmHg at every visit over six years¹³. In people whose pressure was already normal, it reduced worsening from 35 percent to 12 percent¹⁰. In 2015 a trial that compared a pressure-lowering drop with a dummy drop showed for the first time that a single drop preserves visual field¹². The usual first goal is a pressure 20 to 30 percent below your starting level, adjusted to how advanced the damage is⁶.

Eye drops. Most people start with a once-daily prostaglandin drop such as latanoprost, which lowers pressure by about 6 to 8 mmHg²³. Other classes of drop are beta blockers, alpha agonists, carbonic anhydrase inhibitors, rho-kinase inhibitors, and combinations of these¹⁸. Options approved since 2017 include netarsudil (Rhopressa, 2017), latanoprostene bunod (Vyzulta, 2017), a netarsudil-latanoprost combination (Rocklatan, 2019), omidenepag (Omlonti, 2022), and a preservative-free bimatoprost gel (Zolymbus, 2025)^24,25,65. Side effects depend on the class. Prostaglandins can redden the eye, lengthen lashes and darken the iris. Beta blockers can slow the heart and worsen asthma. Alpha agonists can cause fatigue, dry mouth and allergy. Carbonic anhydrase inhibitors can cause tingling and a metallic taste. Rho-kinase inhibitors commonly cause redness^18,24. Drops only work if they are used every day, which is one reason laser is increasingly offered first¹⁹.

Laser. Selective laser trabeculoplasty (SLT) uses a low-energy laser on the drainage angle to help fluid leave the eye. In the LiGHT trial of 718 people with newly diagnosed glaucoma or high eye pressure, 74 percent of those treated with laser first needed no drops at three years¹⁹. At six years, 70 percent were still at target without drops or surgery, fewer had worsened (20 percent versus 27 percent on drops), and fewer needed glaucoma surgery²⁰. The LiGHT investigators concluded that laser should be offered as a first-line treatment¹⁹. For angle-closure, a laser iridotomy makes a small opening in the iris to relieve the block⁷. In people with narrow angles but no disease, preventive laser gave only a modest benefit in a large Chinese trial³¹.

Slow-release implants. Two FDA-approved implants release medicine inside the eye for months. Durysta (bimatoprost, 2020) is a one-time implant that lowered pressure by about 5 to 8 mmHg in its trials; it cannot be repeated in the same eye²¹. iDose TR (travoprost, 2023) is anchored in the drainage angle, and in January 2026 the FDA approved labelling that allows it to be replaced²². In its trials iDose TR matched timolol drops for the first three months but not over the following nine, so some people still need drops²². Both reduce the need for drops; neither is a cure.

Surgery. Minimally invasive glaucoma surgery (MIGS) uses tiny stents or channels, often placed during cataract surgery, to improve drainage with less risk than traditional surgery. In the pivotal trial of the iStent inject, 76 percent of eyes achieved a 20 percent pressure drop without drops at two years, against 62 percent with cataract surgery alone²⁶. The Hydrus stent kept two-thirds of eyes medication-free at five years²⁷. An implant-free MIGS procedure, OMNI Ultra, was cleared in August 2026²⁸. For advanced or fast-moving glaucoma, two operations lower pressure the most, with more risk: trabeculectomy, which creates a new drainage channel, and a tube shunt, a tiny tube that drains fluid. Both bring pressure into the low teens over five years²⁹. In people over 50 with angle-closure glaucoma or very high pressure from angle closure, removing the natural lens can be offered as a first-line option^7,30.

Our guide to glaucoma treatment: drops, laser, MIGS and surgery compares the options in detail.

New treatments for glaucoma in clinical trials

Every approved treatment lowers pressure. Research is moving in two directions: new ways to lower pressure, and treatments that protect the optic nerve directly. None of the nerve-protection treatments is approved yet. The trials below are the ones most likely to change care in the next few years. Trial status is as posted on ClinicalTrials.gov when checked on October 18, 2026; some records had not been updated since 2023 or 2024^37–48.

What this means for you: if your glaucoma is progressing despite good pressure control, ask your specialist whether a nicotinamide or other nerve-protection trial is enrolling near you. Nicotinamide is sold over the counter, but the doses in these trials (1.5 to 3 grams a day) are far above dietary amounts. Long-term safety is what the trials are testing, and a 2026 review of all the human studies concluded the evidence is not yet enough to support routine high-dose use³⁶. Do not start it without telling your eye doctor and your physician.

Living with glaucoma

With treatment and follow-up, most people with glaucoma keep sight in at least one eye for life⁶⁷. The things that most affect that outcome are within reach^6,18:

• Use your drops every day and tell your doctor if you cannot; there is almost always another option, including laser.
• Keep every follow-up. Glaucoma is tracked by change over time, and a missed year is a missed measurement.
• Know your target pressure and ask at each visit whether you are at it.
• Tell every doctor you see that you have glaucoma, especially before any steroid prescription.
• Check driving safety with your eye doctor if side vision is affected; the loss is easy to underestimate.
• Ask about low-vision help early if central vision is involved. Lighting, contrast and scanning habits make a real difference.
• Tell relatives. Parents, siblings and children should be examined¹⁵.

Where integrative care fits

Netra Eye Institute is an acupuncture and Oriental medicine practice. We do not diagnose, monitor or treat glaucoma, and nothing we offer lowers eye pressure enough to replace drops, laser or surgery. Our role is adjunctive: care that sits alongside your ophthalmologist's treatment, with the evidence explained before you start. Here is what the research shows for the approaches people ask about most.

What working with Netra looks like. We ask first that you have an ophthalmologist or optometrist managing your glaucoma, with a target pressure and a monitoring plan. If you do not, arranging that comes before anything else. Then we review the pressures, scans and field tests you already have, and look at the factors around the nerve that your specialist may not have time for: night-time blood pressure, sleep apnea symptoms, exercise habits, diet, stress and sleep. We offer acupuncture and, where appropriate, Chinese herbal medicine within Netra Restoration Therapy (NRT), and we check every herb against your medicines. NRT is adjunctive. It does not lower eye pressure, regenerate the optic nerve or restore lost visual field, and we do not claim that it slows glaucoma; that is a question only a controlled trial can answer, and none has been done. For the Ayurvedic perspective, see Ayurveda and glaucoma; for the science of blood flow to the nerve, see ocular blood flow and the optic nerve; for the habits that affect eye pressure, see exercise, diet, sleep and glaucoma.

Outlook

Vision lost to glaucoma does not come back^1,2. But glaucoma is slow, treatment works, and the trials that proved it also show how much the outcome depends on the pressure being kept down year after year^8,11,13. In the 20-year follow-up of the Ocular Hypertension Treatment Study, about three-quarters of people who started with high eye pressure had no visual field loss in either eye, although nearly half had developed some sign of glaucoma⁸. In a Swedish study that followed 592 treated glaucoma patients to the end of life, about 1 in 6 became blind in both eyes and about 4 in 10 lost sight in one eye; the rest kept useful vision⁶⁷. The best predictors of keeping sight are early diagnosis, a pressure kept at target, and follow-up that is never missed. The next decade is likely to bring the first treatments that protect the nerve itself; the late-stage nicotinamide trials will report from 2027^37,38.

Frequently asked questions

Is there a cure for glaucoma?

No. Treatment lowers eye pressure to protect the nerve from further damage; it cannot repair damage already done^1,2. Researchers are testing treatments that protect the nerve directly, but none is approved yet.

Can glaucoma be reversed?

No. Nerve fibres and visual field lost to glaucoma do not return¹. What treatment does well is keep the vision you still have². Read more in can glaucoma be reversed? What can and cannot be restored.

Is glaucoma hereditary?

Partly. A parent or sibling with glaucoma raises your risk substantially, and ancestry matters^2,4,6. But most adult glaucoma involves many genes rather than one, so routine genetic testing is not recommended⁶³. Many people with a family history never develop it, and many with glaucoma have no family history. Relatives of someone with glaucoma should have regular eye exams¹⁵.

What are the stages of glaucoma?

Doctors grade glaucoma by how much damage the nerve and visual field show, usually as mild, moderate or severe, and set a lower target pressure for more advanced disease^6,68. Ocular hypertension and "glaucoma suspect" are not stages of glaucoma; they are higher-risk states that may never become it^2,8.

What are the side effects of glaucoma eye drops?

It depends on the class. Prostaglandin drops can cause red eyes, longer lashes and a darker iris. Beta blockers can slow the heart rate and affect breathing. Alpha agonists can cause tiredness, dry mouth and allergy. Carbonic anhydrase inhibitors can cause tingling and a metallic taste. Rho-kinase inhibitors cause redness in about half of users^18,24. If side effects stop you using a drop, tell your doctor rather than stopping; laser and implants are alternatives^19,21.

What is normal eye pressure?

Usually 10 to 20 mmHg¹⁴. But glaucoma can develop at normal pressure, and many people with raised pressure never develop it: in the Ocular Hypertension Treatment Study, about half of people with pressures of 24 to 32 had not developed glaucoma after 20 years⁸. So the number is read alongside the nerve and the visual field¹⁴. See normal eye pressure range.

Can you have glaucoma with normal eye pressure?

Yes. Many people with glaucoma have pressure in the normal range, and lowering pressure still slows the disease^6,10. See our guide to normal-tension glaucoma.

Will I go blind from glaucoma?

Untreated glaucoma is the leading cause of irreversible blindness worldwide⁵. With treatment and follow-up, most people do not go blind: in a Swedish study that followed treated patients for life, about 1 in 6 became blind in both eyes⁶⁷. The risk is highest with late diagnosis, high pressure and missed follow-up. See glaucoma risk factors beyond eye pressure.

Can acupuncture, diet or vitamin B3 help glaucoma?

None replaces pressure-lowering treatment. Acupuncture has very-low-certainty evidence from small trials^49,51; leafy greens are linked to lower risk in observational studies⁵⁴; high-dose vitamin B3 is in late-stage trials and should not be taken outside one without medical advice^36,37. Netra offers acupuncture as adjunctive care alongside your specialist's treatment, with the evidence explained.

Sources

1. National Eye Institute. Glaucoma. Updated July 28, 2020. link
2. American Academy of Ophthalmology. What is glaucoma? Symptoms, causes, diagnosis, treatment. March 4, 2026. link
3. Ehrlich JR, et al. Prevalence of glaucoma among US adults in 2022. JAMA Ophthalmology. 2024. link
4. Centers for Disease Control and Prevention. Glaucoma. May 15, 2024. link
5. Tham YC, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014. link
6. American Academy of Ophthalmology. Primary Open-Angle Glaucoma Preferred Practice Pattern 2025. Published February 2026. link
7. American Academy of Ophthalmology. Primary Angle-Closure Disease Preferred Practice Pattern 2025. Published February 2026. link
8. Kass MA, et al. The Ocular Hypertension Treatment Study. Archives of Ophthalmology. 2002.; 20-year follow-up, JAMA Ophthalmology 2021. link 1link 2
9. Gordon MO, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002. link
10. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. American Journal of Ophthalmology. 1998. link
11. Heijl A, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002. link
12. Garway-Heath DF, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015. link
13. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. American Journal of Ophthalmology. 2000. link
14. American Academy of Ophthalmology. Eye pressure. May 24, 2022. link
15. American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern. February 11, 2026. link
16. U.S. Preventive Services Task Force. Primary open-angle glaucoma: screening. May 24, 2022. link
17. Mayo Clinic. Glaucoma: symptoms and causes. November 5, 2024. link
18. Mayo Clinic. Glaucoma: diagnosis and treatment. link
19. Gazzard G, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT). Lancet. 2019. link
20. Gazzard G, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) trial: six-year results. Ophthalmology. 2023. link
21. U.S. Food and Drug Administration. DURYSTA (bimatoprost intracameral implant) prescribing information. Label effective October 2024. link
22. U.S. Food and Drug Administration. iDose TR (travoprost intracameral implant) prescribing information, with readministration, effective March 2026.; Optometry Times. FDA approves NDA labeling supplement allowing re-administration of iDose TR. January 28, 2026. link 1link 2
23. U.S. Food and Drug Administration. XALATAN (latanoprost) prescribing information. link
24. U.S. Food and Drug Administration. RHOPRESSA (netarsudil) prescribing information, effective January 2026. link
25. U.S. Food and Drug Administration. Drugs@FDA approval records for Vyzulta (November 2, 2017), Rocklatan (March 12, 2019) and Omlonti (September 22, 2022). link
26. Samuelson TW, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract. Ophthalmology. 2019. link
27. Ahmed IIK, et al. Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent. Ophthalmology. 2022. link
28. Ophthalmology Times. FDA clears OMNI Ultra surgical system. August 11, 2026. link
29. Gedde SJ, et al. Primary Tube Versus Trabeculectomy Study: review. Current Opinion in Ophthalmology. 2023. link
30. Azuara-Blanco A, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE). Lancet. 2016. link
31. He M, et al. Laser peripheral iridotomy for the prevention of angle closure (ZAP). Lancet. 2019. link
32. Eyewire News. FDA accepts Nicox's NDA for NCX 470. August 27, 2026.; Nicox. NCX 470 Denali phase 3 results. link 1link 2
33. Hui F, et al. Improvement in inner retinal function in glaucoma with nicotinamide supplementation: a crossover randomized clinical trial. Clinical and Experimental Ophthalmology. 2020. link
34. De Moraes CG, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmology. 2022. link
35. Nicotinamide in normal-tension glaucoma: a randomised crossover trial. British Journal of Ophthalmology. 2026. link
36. Systematic review of nicotinamide in glaucoma. Nutrients. September 2026. link
37. ClinicalTrials.gov. NCT05275738. The Glaucoma Nicotinamide Trial (Umeå University, with the Centre for Eye Research Australia and Singapore National Eye Centre). link
38. ClinicalTrials.gov. NCT05405868. NAMinG: nicotinamide in glaucoma (University College London). link
39. ClinicalTrials.gov. NCT06731582. Nicotinamide for glaucoma (Singapore Eye Research Institute). link
40. ClinicalTrials.gov. NCT05695027. Nicotinamide and pyruvate for glaucoma (Columbia University). link
41. Rossetti L, et al. Can treatment with citicoline eyedrops reduce progression in glaucoma? Journal of Glaucoma. 2020. link
42. ClinicalTrials.gov. NCT05710198. Citicoline eye drops in glaucoma progression (Omikron Italia). link
43. Goldberg JL, et al. Intravitreal ciliary neurotrophic factor (NT-501) in glaucoma: phase 1. Ophthalmology Science. 2023. link
44. ClinicalTrials.gov. NCT02862938 and NCT04577300. NT-501 in glaucoma (Stanford University). link
45. ClinicalTrials.gov. NCT07770685. ASP2767 in glaucoma-related optic nerve damage (Astellas). link
46. ClinicalTrials.gov. NCT07290244. ER-100 epigenetic therapy in glaucoma and NAION (Life Biosciences). link
47. Bayer. Bayer completes acquisition of Perfuse Therapeutics. June 17, 2026. link
48. Glance. Positive data reported in Qlaris Bio's phase 2 trials. February 6, 2025.; ClinicalTrials.gov NCT06030193 and NCT07354516. link
49. Law SK, Li T. Acupuncture for glaucoma. Cochrane Database of Systematic Reviews. 2020. link
50. Acupuncture and electroacupuncture for intraocular pressure: a randomized trial. 2020. link
51. Acupuncture in normal-tension glaucoma: a 24-week randomized sham-controlled trial. Complementary Therapies in Medicine. 2026. link
52. Jasien JV, et al. Intraocular pressure rise in subjects with and without glaucoma during four common yoga positions. PLoS One. 2015. link
53. Exercise and glaucoma: a review. Acta Ophthalmologica. 2018. link
54. Kang JH, et al. Association of dietary nitrate intake with primary open-angle glaucoma. JAMA Ophthalmology. 2016. link
55. Kim J, et al. Intraocular pressure, glaucoma, and dietary caffeine consumption: a gene-diet interaction study. Ophthalmology. 2021. link
56. Water-drinking test in glaucoma: systematic review and meta-analysis. Eye. 2024. link
57. American Academy of Ophthalmology. Does marijuana help treat glaucoma? January 21, 2026. link
58. Ginkgo biloba in glaucoma: systematic review and meta-analysis. 2025. link
59. Dada T, et al. Mindfulness meditation reduces intraocular pressure, lowers stress biomarkers and modulates gene expression in glaucoma: a randomized controlled trial. Journal of Glaucoma. 2018. link
60. Smoking and primary open-angle glaucoma: meta-analysis. International Ophthalmology. 2026. link
61. Charlson ME, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology. 2014. link
62. Obstructive sleep apnea in glaucoma: meta-analysis. Journal of Current Glaucoma Practice. 2021. link
63. American Academy of Ophthalmology. Recommendations for genetic testing of inherited eye diseases. 2014. link
64. Glaucoma Research Foundation. Glaucoma facts and stats. Updated March 12, 2025. link
65. U.S. Food and Drug Administration. Drugs@FDA approval record, Zolymbus (bimatoprost 0.01% preservative-free gel), September 9, 2025. link
66. National Eye Institute. Types of glaucoma. Updated December 5, 2024. link
67. Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open-angle glaucoma. American Journal of Ophthalmology. 2013. link
68. ICD-10-CM 2026, category H40 glaucoma: 7th-character stage codes 0 unspecified, 1 mild, 2 moderate, 3 severe, 4 indeterminate. link